RNAM
Avidity Biosciences, Inc.Company Information
- Company Name
- Avidity Biosciences, Inc.
- CIK
- CIK0001599901
- Category
- Large accelerated filer
- Ticker: Exchange
- RNAM: Nasdaq, RNA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RNAM
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-01-21
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 805,989
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 8,000
- Shares outstanding
- 137,710,000
- Ownership
- 0.01%
Earnings Market Reaction
- Filing date
- 2026-02-23
- Price on filing date
- —
- 1-month reaction
- …
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 383 | 350 | 244 | 254 | 220 | 370 | 576 | 471 | 185 | 86 | 154 | 119 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 1,798 | 1,966 | 1,251 | 1,435 | 1,542 | 1,622 | 1,329 | 934 | 611 | 555 | 595 | 597 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Current | 1,314 | 1,526 | 939 | 1,126 | 1,282 | 1,218 | 723 | 444 | 410 | 457 | 423 | 468 | ||||||
| Prepaid Expense And Other Assets Current | 102 | 90 | 67 | 55 | 41 | 33 | 30 | 19 | 16 | 13 | 18 | 11 | ||||||
| Property Plant And Equipment Net | 23 | 22 | 21 | 16 | 13 | 9 | 8 | 9 | 8 | 8 | 8 | 8 | ||||||
| Restricted Cash Noncurrent | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 51 | 53 | 4 | 5 | 6 | 6 | 7 | 8 | 8 | 9 | 8 | 8 | ||||||
| Other Assets Noncurrent | 82 | 91 | 91 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,958 | 2,134 | 1,369 | 1,459 | 1,564 | 1,641 | 1,347 | 951 | 629 | 573 | 611 | 614 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | - | - | - | 54 | 70 | 50 | 41 | 37 | 34 | 32 | 32 | 34 | ||||||
| Accounts Payable Current | 12 | 10 | 4 | - | 8 | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities And Other Liabilities | 157 | 137 | 95 | - | 65 | - | - | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Deferred Compensation Liability Current | - | - | 18 | 13 | 4 | 18 | 13 | 8 | 14 | 11 | 7 | 6 | ||||||
| Liabilities Current | 195 | 170 | 135 | 85 | 98 | 91 | 84 | 75 | 81 | 49 | 45 | 48 | ||||||
| Operating Lease Liability Current | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | ||||||
| Contract With Customer Liability Current | 22 | 19 | 14 | 14 | 21 | 20 | 27 | 26 | 28 | 2 | 4 | 5 | ||||||
| Operating Lease Liability Noncurrent | 45 | 46 | 1 | 2 | 3 | 4 | 5 | 5 | 6 | 7 | 6 | 7 | ||||||
| Contract With Customer Liability Noncurrent | 29 | 32 | 40 | 43 | 38 | 42 | 38 | 40 | 41 | 0 | 0 | 0 | ||||||
| Liabilities | 269 | 248 | 176 | 130 | 139 | 137 | 126 | 121 | 128 | 56 | 52 | 55 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 3,264 | 3,225 | 2,357 | 2,335 | 2,315 | 2,287 | 1,932 | 1,471 | 1,071 | 1,030 | 1,020 | 971 | ||||||
| Stockholders Equity | 1,689 | 1,886 | 1,193 | 1,329 | 1,425 | 1,503 | 1,221 | 831 | 501 | 517 | 559 | 559 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 3 | 2 | 2 | 3 | 3 | 7 | -0 | -0 | 0 | -2 | -3 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -1,578 | -1,341 | -1,166 | -1,009 | -893 | -791 | -710 | -640 | -571 | -510 | -458 | -411 | ||||||
| Liabilities And Stockholders Equity | 1,958 | 2,134 | 1,369 | 1,459 | 1,564 | 1,641 | 1,347 | 951 | 629 | 573 | 611 | 614 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | 400 | ||||||
| Common Stock Shares Issued | 151 | 147 | 121 | 121 | 120 | 119 | 109 | 96 | 79 | 74 | 74 | 71 | ||||||
| Shares Outstanding | 151 | 147 | 121 | 121 | 120 | 119 | 109 | 96 | 79 | 74 | 74 | 71 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAvidity Biosciences, Inc. (RNAM) — SEC Financial Statements & Analysis
Avidity Biosciences, Inc. (RNAM) is a pharmaceutical preparations company, incorporated in DE. Avidity Biosciences, Inc. trades on Nasdaq as: RNAM, RNA. Avidity Biosciences, Inc. (RNAM)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-23. Based on its latest SEC filing (Form 10-Q, period ending 2025-12-31), On profitability, Avidity Biosciences, Inc. posts an operating margin of -3977.30%, a net margin of -3650.39%, a Return on Equity (ROE) of -43.98%, a Return on Assets (ROA) of -38.88%, and a Return on Invested Capital (ROIC) of -59.53%. Per share, it reports EPS of $-4.97, diluted EPS of $-4.97, free cash flow per share of $-4.82, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 72.11% year-over-year, net income growth of 112.42% year-over-year, and EPS growth of 72.12% year-over-year. On the balance sheet, it maintains a current ratio of 9.20x, a quick ratio of 8.68x, working capital of $1.60B, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, free cash flow of $-663.76M (TTM), and net debt of $-385.31M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-4.97
- ROE TTM
- -43.98%
- ROA TTM
- -38.88%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-663.76M
- Net Revenue TTM Growth 1Y
- 72.11%
Data as of 2025-12-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Avidity Biosciences, Inc. in?
Avidity Biosciences, Inc. (RNAM) operates in the Pharmaceutical Preparations industry.
What exchange does RNAM trade on?
Avidity Biosciences, Inc. (RNAM) trades on the Nasdaq.
Where is Avidity Biosciences, Inc. incorporated?
Avidity Biosciences, Inc. is incorporated in DE.
When was Avidity Biosciences, Inc. (RNAM)'s most recent SEC filing?
Avidity Biosciences, Inc. (RNAM)'s most recent SEC filing is a Form 10-K for the period ended 2025-12-31, filed with the SEC on 2026-02-23.
What is RNAM's EPS (earnings per share)?
Avidity Biosciences, Inc. (RNAM)'s trailing twelve month EPS is $-4.97 as of 2025-12-31.
What is RNAM's ROE (return on equity)?
Avidity Biosciences, Inc. (RNAM)'s trailing twelve month Return on Equity (ROE) is -43.98% as of 2025-12-31.
What is RNAM's ROA (return on assets)?
Avidity Biosciences, Inc. (RNAM)'s trailing twelve month Return on Assets (ROA) is -38.88% as of 2025-12-31.
What is RNAM's ROIC (return on invested capital)?
Avidity Biosciences, Inc. (RNAM)'s trailing twelve month Return on Invested Capital (ROIC) is -59.53% as of 2025-12-31.